■ MANTIS

CDMO, Small Molecule
& Bioprocess Intelligence
Updated 05 June 2026  ·  75 companies monitored
1,819
Signals
30 days
75
Companies
tracked
150
Predictions
logged
Leading narrative Biosimilar Market Expansion Rolling 7 days
Leading tech themeBioprocess PlatformPatent & publication signals · 30 days
Story of the week
↘ Fading Biosimilar Market Expansion
395signals this week · 26companies active
Signal of the week
FDA Action ●●●●○○○○  4/10
Drug Approval: DIVALPROEX SODIUM (manufactured by Lupin)
Narrative tracker — signals · rolling 7 days
01Biosimilar Market Expansion395
02GLP-1 Manufacturing Capacity391
03Cell & Gene Therapy Manufacturing339
04India Generics & API Expansion198
05Sector Consolidation & M&A160
06ADC Outsourcing Wave125
07Manufacturing Capacity Expansion89
08Generic & Biosimilar Market Dynamics73
09Next-Gen Manufacturing Technology54
10FDA / Regulatory Pressure43
Narrative momentum — rolling 30 days
Narrative momentum — 30 days

Each line tracks one sector narrative — 7-day rolling average of signal volume and cross-source breadth, updated daily.

This week in pharma manufacturing
📰Regeneron and CytomX extend cancer therapy partnership to $4bn dealRegeneron Pharmaceuticalspharmaceutical-technology.comCapacity 📰ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’Gilead Sciencesfiercebiotech.comM&A 📰Gilead scraps lead arthritis drug from $405M MiroBio buyout in latest blow to BTLA agonist fieldGilead Sciencesfiercebiotech.comM&A 📰With Cencora pact, Gilead looks to grow CAR-T treatment center networkGilead Sciencesfiercepharma.comCapacity 📰Regeneron pays $37M, adds $2B in biobucks to expand CytomX pactRegeneron Pharmaceuticalsfiercebiotech.comCapacity 📰AbbVie receives EC approval for Aquipta to treat migraineAbbViepharmaceutical-technology.com 📰Cellares and TScan to assess automated manufacturing of TSC-101 therapyCellarespharmaceutical-technology.com 📰Roche’s giredestrant secures FDA priority review for breast cancerRochepharmaceutical-technology.com
Deal intelligence — partnerships & capacity moves
🤝Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseasesEli Lilly3 🤝ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyoutEli Lilly5 🤝ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’Gilead Sciences5 🤝Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continuesEli Lilly5 🤝Gilead scraps lead arthritis drug from $405M MiroBio buyout in latest blow to BTLA agonist fieldGilead Sciences5 🏗Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndromeEli Lilly4 🏗Regeneron pays $37M, adds $2B in biobucks to expand CytomX pactRegeneron Pharmaceuticals4 🏗GLP-1 manufacturer CordenPharma strikes deal for peptide CDMO, lining up new production sites in US and ChinaCordenPharma5
Demand drivers — pharma pipeline signals Pharma pipeline signals
📈Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitorsEli Lilly3 📈AbbVie receives EC approval for Aquipta to treat migraineAbbVie2 📈AstraZeneca, Daiichi Sankyo’s Datroway receives FDA approval for TNBCAstraZeneca4 📈Eli Lilly to buy trio of vaccine developers in $3.8bn outlayEli Lilly2 📈FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapyAstraZeneca4 📈FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limboAstraZeneca2
How it works
01
Collect
Signals ingested daily across clinical trials, FDA and EMA regulatory filings, scientific publications, SEC disclosures, hiring patterns, and industry news. Each signal is scored and classified by therapy area and signal type.
02
Converge
When multiple independent sources flag the same company within a rolling window, a convergence alert fires. Cross-source agreement is the signal — a single news article is noise; a clinical filing, a hiring surge, and a regulatory action on the same company are not.
03
Synthesise
A weekly synthesis covers what moved, what it implies, and where to look next. Predictions are made explicitly and logged — then scored as outcomes become known. Company-level intelligence briefs covering signal momentum, risk flags, and capability profiles are available on request.
Signal sources — rolling 30 days
News929
Clinical Trials451
Patent Cliff174
Science139
Hiring68
FDA37
SEC Filings21

Mantis runs continuously — ingesting signals, scoring convergence, and tracking whether its predictions come true. It does not summarise headlines. It identifies when independent data sources start moving in the same direction on the same company, and asks what that combination of evidence implies. Built for the pharma advisor or investor who needs to know which CDMOs are moving before the headlines explain why.

CDMO selection · competitive intelligence · strategic advice
Intelligence briefings and company assessments available on request.
[email protected] →
[email protected] © 2026 Mantis Intelligence.

Mantis Intelligence is not authorised or regulated by the Financial Conduct Authority or any other financial regulator. Content is produced by automated systems and artificial intelligence for information and research purposes only. Nothing on this site constitutes investment advice, a personal recommendation, or a solicitation. Past signal patterns are not predictive of future events or outcomes.

Signals are sourced from public regulatory filings (FDA, EMA, SEC EDGAR), clinical trial registries, scientific publication databases, and publicly available news feeds. This site sets no cookies and collects no personal data.